In vitro cell death of activated lymphocytes in Omenn's syndrome
- 1 November 1997
- journal article
- case report
- Published by Wiley in European Journal of Immunology
- Vol. 27 (11) , 2765-2773
- https://doi.org/10.1002/eji.1830271104
Abstract
Omenn's syndrome (OS) is characterized by erythrodermia, hepatosplenomegaly, lymphadenopathy, hypereosinophilia and elevated IgE levels associated with increased susceptibility to severe infections. Peripheral blood T cells, though usually present in normal number, show an activated phenotype (including an increased expression of CD95/Fas), a Th2 pattern of cytokine secretion and defective proliferative response to mitogens. In this report, we demonstrate that T cells from patients with OS undergo an excessive cell death in vitro resulting from two mechanisms. First, a substantial number of peripheral blood lymphocytes from OS patients die in unstimulated cultures (p = 0.009 vs. healthy controls). This spontaneous apoptosis is associated with reduced expression of bcl‐2 gene product (p < 0.05) and can be prevented by addition of interleukin (IL)‐2 (which also prevents down‐modulation of bcl‐2), while is independent from CD95 signaling. Second, lymphocytes from OS patients are highly susceptible to activation‐induced cell death (AICD) induced with mitogens. This mechanism is largely independent from IL‐2, while it can be significantly inhibited blocking CD95 with an IgG2b monoclonal antibody (mAb). The dependence of AICD from signals transduced via CD95 was confirmed showing that cross‐linking CD95 with an IgM mAb induces a higher cell death in purified CD4+ CD45RO+ cells from OS patients than in controls (comparable for CD95 expression). Both mechanisms of cell death observed in this study result from lymphocyte hyperactivation occurring in vivo in these patients and may contribute to functional T cell defects of OS.Keywords
This publication has 57 references indexed in Scilit:
- Interleukin‐2 receptor common γ‐chain signaling cytokines regulate activated T cell apoptosis in response to growth factor withdrawal: Selective induction of anti‐apoptotic (bcl‐2, bcl‐xL) but not pro‐apoptotic (bax, bcl‐xS) gene expressionEuropean Journal of Immunology, 1996
- Treatment of Omenn syndrome by bone marrow transplantationThe Journal of Pediatrics, 1995
- Fas(CD95)/FasL interactions required for programmed cell death after T-cell activationNature, 1995
- Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomasNature, 1995
- Molecular cloning and expression of the fas ligand, a novel member of the tumor necrosis factor familyCell, 1993
- Severe combined immunodeficiency: A retrospective single-center study of clinical presentation and outcome in 117 patientsThe Journal of Pediatrics, 1993
- Novel T-Lymphocyte Population in Combined Immunodeficiency with Features of Graft-versus-Host DiseaseNew England Journal of Medicine, 1989
- Clinical and immunological findings in four infants with Omenn's syndrome: A form of severe combined immunodeficiency with phenotypically normal T cells, elevated IgE, and eosinophiliaClinical Immunology and Immunopathology, 1987
- A lymphoproliferative syndrome, “cutaneous dystrophy” and combined immune deficiency with lack of helper T-cell factorClinical Immunology and Immunopathology, 1982
- Combined immunodeficiency and reticuloendotheliosis with eosinophiliaThe Journal of Pediatrics, 1974